Table 4. Analysis of relationships between vimentin and clinicopathological variables in NSCLC.

Clinicalpathological Variable	No. of Studies	model	Cases (N)	Pooled OR	95% CI		P value	Test for Heterogeneity
								P value	I2(95%CI)	H(95%CI)
Age(≥ 60/<60)	24	Random effect	2810	0.927	0.789	1.088	0.353	0.799	0%(0%-45%)	1.0(1.0–1.3)
Gender(male/female)	25	Random effect	3105	1.122	0.944	1.332	0.192	0.473	0%(0%-44%)	1.0(1.0–1.3)
Diameter(>3.0cm/≤3.0 cm)	11	Random effect	1166	1.317	0.919	1.888	0.133	0.123	34%(0%-68%)	1.2(1.0–1.8)
Histology(SCC/AC)	20	Random effect	2259	0.821	0.684	0.986	0.034	0.644	0%(0%-48%)	1.0(1.0–1.4)
Smoking status(yes/no)	12	Random effect	2050	1.362	1.105	1.678	0.004	0.677	0%(0%-57%)	1.0(1.0–1.5)
Differentiation(poorly/moderate or well)	25	Random effect	2856	2.133	1.664	2.735	<0.001	0.048	34%(0%-60%)	1.2(1.0–1.6)
T stage(T2 or T3/T1)	6	Random effect	957	1.044	0.704	1.548	0.830	0.498	0%(0%-75%)	1.0(1.0–2.0)
TNM stages(III or IV/I or II)	20	Random effect	2661	3.069	1.894	4.974	<0.001	<0.001	80%(70%-87%)	2.3(1.8–2.8)
Vascular invasion(yes/no)	4	Random effect	722	3.492	1.063	11.472	0.039	0.001	83%(56%-93%)	2.4(1.5–3.9)
Lymph node metastasis(yes/no)	20	Random effect	2395	2.628	1.857	3.718	<0.001	<0.001	64%(41%-77%)	1.7(1.3–2.1)
Recurrence(yes/no)	3	Random effect	490	1.632	1.054	2.529	0.028	0.984	0%(0%-490%)	1.0(1.0–3.1)
Distant metastasis	2	Random effect	248	3.975	0.724	21.807	0.112	0.069	70% (-)	(-)
Marginal invasion	2	Random effect	477	2.429	0.789	7.473	0.122	0.025	80% (-)	(-)
Pleural invasion	2	Random effect	290	2.344	1.395	3.393	0.001	0.794	0% (-)	(-)

SCC: squamous cell carcinoma, AC: Adenocarcinoma.